Many people are interested in the latest research in nutrition. The focus of recent studies is on how to target specific amino acids to treat thyroid cancer, fibromyalgia, obesity and several other chronic health conditions. One exciting area of research involves the use of l-carnitine to treat anxiety and depression in addition to boosting brain function. This new approach to treating depression is based on the recognition that excess amounts of the amino acid l-carnitine can cause an imbalance in brain chemistry that contributes to mood disorders like depression. In addition to treating current mental illnesses, the use of l-carnitine as an adjunct to current treatments for obesity may be effective in preventing future bouts with obesity.
Clinical trials have shown that dietary supplements that contain l-carnitine improve overall health and ward off or even prevent certain types of cancer. Another area of latest research relates dietary supplements to increased immune system activity that can help reduce the severity of outbreaks of acne and other skin problems. Another area of medical attention that benefits from l-carnitine is the treatment of thyroid cancer. There are two distinct areas of treatment: one uses targeted therapy, while the other relies more on a combination of therapy and nutrition.
Tissue necrosis (TN), the most common type of neoplastic tumor, responds well to a compound called amitriptyline. The second disease model under research is amilastin, which occurs in multiple sclerosis patients and is associated with high-dose chemotherapy. According to recent clinical trials, amilastin can shrink tumors while simultaneously blocking the activity of the primary tumor marker, acetylcholine. When these two activities are combined, the ability to shrink tumors while also preventing acetylcholine from binding to nerve cells is the basis for this new treatment option.
Kinase inhibitors are a key part of the latest in targeted therapies for neuroblastoma, a disease that affects almost all of the cells in the body. When these molecules bind to a cell’s receptor, it causes the cell to stop functioning. For this reason, the compound known as MBG is often an important part of an individualized therapy. According to recent clinical trials, mibg prevents the formation of protein aggregates that are made from amino acids by the immune system. This prevents inflammation, swelling and pain, as well as the production of new blood vessels.
Another compound being tested in clinical trials for the treatment of thyroid cancer is a recently approved nonsteroidal anti-inflammatory agent called prilosec. It works by reducing the symptoms of swelling and pain associated with thyroid cancer. Clinical studies have shown that in conjunction with MBG, the combination of i-131 and prilosec effectively destroys estrogen-receptors and prevents the growth of neoplastic tumors. In addition to reducing symptoms, prilosec appears to be effective in blocking the formation of new blood vessels caused by tumors.
These two promising new agents aim to not only find a cure for cancer, but also to prolong the life expectancy of those diagnosed with this condition. If these studies prove successful, it will be an exciting time for patients who are suffering from this disease. New and innovative treatments for this type of cancer may be the answer to a long-term solution for the millions of people affected by this disease. The latest research into treatments for this type of cancer may be worth watching.